Torsdag 18 September | 12:06:30 Europe / Stockholm

Svenska | English

Oculis Holding

Filter

År

Typ

Språk

Rensa

2025-09-09 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2090,00 ISK | +1,46% | 18,1 MISK

2025-09-04 19:00:00 Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025 2080,00 ISK | +1,96% | 58,1 MISK

2025-09-03 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2040,00 ISK | +2,00% | 450 MISK

2025-09-01 10:00:00 Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences 1990,00 ISK | 0,00% | 4,79 MISK

2025-08-28 10:00:00 Oculis to Participate in Upcoming September Investor Conferences 2080,00 ISK | -2,35% | 63,9 MISK

2025-08-25 10:00:00 Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors 2170,00 ISK | -0,23% | 268 MISK

2025-08-21 22:05:00 Oculis Reports Q2 2025 Financial Results and Provides Company Update 2175,00 ISK | +0,23% | 11,5 MISK

2025-08-21 22:05:00 Oculis birtir uppgjör fyrir annan ársfjórðung 2025 og kynnir áfanga í rekstri félagsins 2175,00 ISK | +0,23% | 11,5 MISK

2025-08-12 10:00:00 Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference 2240,00 ISK | -0,44% | 3,43 MISK

2025-08-12 10:00:00 Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference 2240,00 ISK | -0,44% | 3,43 MISK

2025-08-01 10:00:00 Oculis hækkar lánsheimild sína og fær aðgang að allt að 100 milljónum CHF 2180,00 ISK | +0,46% | 0,46 MISK

2025-08-01 10:00:00 Oculis Upsized Loan Facility to Access up to CHF 100 million 2180,00 ISK | +0,46% | 0,46 MISK

2025-07-09 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2250,00 ISK | -0,88% | 32,0 MISK

2025-06-09 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2510,00 ISK | -1,18% | 16,3 MISK

2025-06-05 10:00:00 Oculis Publishes Results of 2025 Annual General Meeting 2450,00 ISK | +2,08% | 309 MISK

2025-06-05 10:00:00 Oculis birtir niðurstöður aðalfundar 2025 2450,00 ISK | +2,08% | 309 MISK

2025-06-05 10:00:00 Oculis Publishes Results of 2025 Annual General Meeting 2450,00 ISK | +2,08% | 309 MISK

2025-06-03 23:00:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2400,00 ISK | -0,83% | 116 MISK

2025-06-03 10:00:00 Oculis to Participate in Upcoming June Investor Conferences 2420,00 ISK | -1,22% | 61,2 MISK

2025-05-09 22:05:00 Oculis Publishes Invitation to the Annual General Meeting 2470,00 ISK | +2,49%

2025-05-09 22:05:00 Oculis birtir boð á aðalfund 2470,00 ISK | +2,49%

2025-05-09 22:05:00 Oculis Publishes Invitation to the Annual General Meeting 2470,00 ISK | +2,49%

2025-05-07 10:00:00 Oculis to Present at Upcoming May Investor Conferences 2320,00 ISK | -2,52% | 75,3 MISK

2025-05-01 10:00:00 Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

2025-04-25 22:00:00 Oculis Updates Share Capital 2290,00 ISK | +0,44%

2025-04-17 11:00:00 Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award

2025-04-15 10:00:00 Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets 2280,00 ISK | +5,56% | 223 MISK

2025-04-10 14:00:00 Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema 2040,00 ISK | +9,68% | 388 MISK

2025-04-10 10:00:00 Oculis lýkur innritun sjúklinga í báðar DIAMOND fasa 3 rannsóknirnar á OCS-01 sem meðferð við sjónhimnubjúg af völdum sykursýki 2040,00 ISK | +9,68% | 388 MISK

2025-04-10 10:00:00 Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema 2040,00 ISK | +9,68% | 388 MISK

2025-04-09 23:00:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2040,00 ISK | +9,68% | 388 MISK

2025-04-01 10:00:00 Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond 2480,00 ISK | 0,00% | 11,9 MISK

2025-03-20 23:01:00 Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities 2640,00 ISK | +2,33% | 226 MISK

2025-03-14 21:31:47 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2500,00 ISK | -0,40%

2025-03-11 21:30:00 Oculis birtir uppgjör fyrir fjórða ársfjórðung og árið 2024 og kynnir áfanga í rekstri félagsins 2500,00 ISK | +2,46% | 146 MISK

2025-03-11 21:30:00 Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update 2500,00 ISK | +2,46% | 146 MISK

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Oculis Holding

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden